– FRANCE, Paris / USA, NJ – STENTYS (Euronext Paris:STNT), a medical technology company commercializing the world’s first and only Self-Apposing® coronary stent, today announces that the Board of Directors has appointed Christophe Lottin as the new Chief Executive Officer of the Company. Gonzague Issenmann has organized his succession and will ensure a smooth transition over the next quarter.
Christophe Lottin, who has twenty years of experience in cardiology, rose through the sales organization of Boston Scientific and Hexacath France, up to the position of President with responsibility for Benelux, Switzerland and Canada. In particular, he was instrumental in the commercial success of the Optimax coronary stent. In his multiple roles, he had to coordinate the critical departments of a stent company, such as R&D, Clinical and Regulatory affairs.
Gonzague Issenmann, co-founder of STENTYS, commented: “I am extremely proud of what we accomplished over the last 10 years with an amazing team. The Self-Apposing Technology, with numerous technical improvements and clinical milestones, is now world renowned. Today, STENTYS’ profile has evolved and Christophe is the person the Company needs to keep prospering commercially and become a major industry player. I wish him all the success that STENTYS deserves and remain a long term shareholder. ”
Christophe Lottin, Chief Executive Officer of STENTYS, added: “I am honored to assume the leadership of a company that has built a phenomenal reputation for itself in the cardiology community. As a long time cardiovascular device industry insider, I know how STENTYS products strong differentiation is a solid foundation to continue building the company and write a successful story. ”
Michel Darnaud, Chairman of the Board, concluded: “In the name of the Board, I would like to thank Gonzague for his relentless dedication to the company and for the strategic decisions that he has made. It is the sign of an astute entrepreneur to know when to pass the baton to a different profile of leader. I have known Christophe for years and can vouch for his credentials. The board is looking forward to this new phase of the Company’s life.”
About STENTYS
STENTYS is developing and commercializing innovative solutions for the treatment of patients with complex artery disease. STENTYS’ Self-Apposing® drug-eluting stents are designed to adapt to vessels with ambiguous or fluctuating diameters in order to prevent the malapposition problems associated with conventional stents. The APPOSITION clinical trials in the treatment of acute myocardial infarction showed a very low one year mortality rate and a faster arterial healing compared to conventional stents. The company’s product portfolio also includes MiStent SES®, a coronary DES whose new drug delivery mechanism is designed to match vessel response, and is marketed through STENTYS’ commercial network in Europe, the Middle East, Asia and Latin America.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
